Conference call scheduled for 4:30 p.m. ET today End-of-Phase 2 Meeting for Subcutaneous VK2735 for Obesity Planned for 4Q24 Phase 2 Study of Oral VK2735 in Obesity Expected to Begin 4Q24 Results of Phase 2b VOYAGE Study of VK2809 in NASH /MASH With Fibrosis Selected for Oral Presentation at AASLD Positive Phase 1b Results from VK0214 Study in X-ALD Demonstrate Safety, Tolerability and Reductions in Very Long-Chain Fatty Acids and Plasma Lipids Strong Quarter-End Cash Position of $930 Million SAN DIEGO , Oct.
23, 2024 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX ), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its financial results for the third quarter and nine months ended September 30, 2024 , and provided an update on its clinical pipeline and other corporate developments. Highlights from the Quarter Ended September 30, 2024 , and Other Recent Events: "The first three quarters of 2024 have been a productive period for Viking, with positive results announced from four different clinical trials and promising initial findings reported from a new preclinical program," stated Brian Lian , Ph.
D., chief executive officer of Viking. "In Q1, we announced results from the Phase 2 VENTURE trial evaluating subcutaneous VK2735 for obesity, which demonstrated impressive reductions in body weight after 13 weeks of treatment.
We also reported the initial results from a P.